Novel Bombesin Analogues Conjugated with DOTA-Ala(SO3H)-4 aminobenzoic acid and DOTA-Lys(glucose)-4 aminobenzoic acid: Synthesis, Radiolabeling, and Gastrin Releasing Peptide Receptor Binding Affinity

키워드

참고문헌 (34)

1. Abiraj K, "Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors", J. Nucl. Med, 52(12), pp.1970~1978 (2011)
2. "Eur. J. Nucl. Med. Mol. Imaging", 2007, S221~
3. Chen J, "Synthesis, stabilization and formulation of 177Lu-AMBA, a systemic radiotherapeutic agent for gastrin releasing peptide receptor positive tumors", Appl. Radiat. Isot, 66(4), pp.497~505 (2008)
4. Cutler CS, "Current and potential therapeutic uses of lanthanide radioisotopes", Cancer Biother. Radiopharm, 15(6), pp.531~545 (2000)
5. -1,4,7,10-tetraaza-cyclododecane-1,4,7,10-tetraacetic acid-cc49 fab radioimmunoconjugate, "Cancer Res", 1995, 5288~5295
6. Dijkgraaf I, "Pet of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog", J. Nucl. Med, 53(6), pp.947~952 (2012)
7. Faintuch BL, "Comparison of two peptide radiotracers for prostate carcinoma targeting", Clinics(Sao Paulo), 67(2), pp.163~170 (2012)
8. -core, "Bioconjug. Chem", 2008, 2409~2416
9. Gourni E, "Evaluation of a series of new 99mTclabeled bombesin-like peptides for early cancer detection", Anticancer Res, 26(1A), pp.435~438 (2006)
10. Hoffman TJ, "Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells", J. Nucl. Med, 44(5), pp.823~831 (2003)
11. Honer M, "18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors", J. Nucl. Med, 52(2), pp.270~278 (2011)
12. Jiyun S, "99mTc-labeled bombesin(7-14)nh2 with favorable properties for spect imaging of colon cancer", Bioconjug. Chem, 19, pp.1170~1178 (2008)
13. Kukis D, "Optimized conditions for chelation of 90Y-dota immunoconjugates", J. Nucl. Med, 39, pp.2105~2110 (1998)
14. Kwekkeboom D, "Comparison of 111In-DOTA-tyr3-octreotide and 111In-DTPA-octreotide in the same patients : Biodistribution, kinetics, organ and tumor uptake", J. Nucl. Med, 40, pp.762~767 (1999)
15. Lantry LE, "177Lu-AMBA : Synthesis and characterization of a selective 177Lulabeled grp-r agonist for systemic radiotherapy of prostate cancer", J. Nucl. Med, 47(7), pp.1144~1152 (2006)
16. Lee SY, "Radiolabeling of monoclonal anti-cd105 with 177Lu for potential use in radioimmunotherapy", Appl. Radiat. Isot, 67(7-8), pp.1366~1369 (2009)
17. Leonard TN, "Serum stabilities of short tryptophan-and argininerich antimicrobial peptide analogs", Plus One, 5(9), pp.1~8 (2010)
18. Maecke HR, "8Ga-labeled peptides in tumor imaging", J. Nucl. Med., 46(Suppl 1), pp.172S~178S (2005)
19. Miao Y, "Tumor-targeting properties of 90Y and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model", Nucl. Med. Biol, 32(5), pp.485~493 (2005)
20. Mu L, "In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting grpr-positive tumors", Bioconjug. Chem, 21(10), pp.1864~1871 (2010)
21. Okarvi SM, "Peptide-based radiopharmaceuticals : Future tools for diagnostic imaging of cancers and other diseases", Med. Res. Rev, 24(3), pp.357~397 (2004)
22. Pippin CG, "Lead(ii)complexes of 1, 4, 7, 10-tetraazacyclododecane-n, n′, n′′, n′′′-tetraacetate : Solution chemistry and application to tumor localization with 203Pb-labeled monoclonal antibodies", Inorg. Chem. Acta, 239, pp.43~51 (1995)
23. Rogers BE, "Micropet imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue", Bioconjug. Chem, 14(4), pp.756~763 (2003)
24. Ruegg CL, "Improved in vivo stability and tumor targeting of bismuth-labeled antibody", Cancer Res, 50, pp.4221~4226 (1990)
25. Schottelius M, "Improvement of pharmacokinetics of radioiodinated tyr3-octreotide by conjugation with carbohydrates", Bioconjug. Chem, 13(5), pp.1021~1030 (2002)
26. -labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors, "Bioconjug. Chem", 2008, 2432~2439
27. nh2 : An in vitro, "in vivo assessment of the targeting ability of this new radiopharmaceutical for pc-3 human prostate cancer cells", Nucl. Med. Biol, 30(2), pp.101~109 (2003)
28. Smith CJ, "Gastrin releasing peptide(grp)receptor targeted radiopharmaceuticals : A concise update", Nucl. Med. Biol, 30(8), pp.861~868 (2003)
29. Smith CJ, "Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes", Nucl. Med. Biol, 32(7), pp.733~740 (2005)
30. Wester HJ, "Pet imaging of somatostatin receptors : Design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide", Eur. J. Nucl. Med. Mol. Imaging, 30(1), pp.117~122 (2003)
31. Wester HJ, "Comparison of radioiodinated toc, toca and mtr-toca : The effect of carbohydration on the pharmacokinetics", Eur. J. Nucl. Med. Mol. Imaging, 29(1), pp.28~38 (2002)
32. Yubin M, "111In-labeled lactam bridge-cyclized r-melanocyte stimulating hormone peptide analogues for melanoma imaging", Bioconjugate Chem, 19, pp.539~547 (2008)
33. Zhang H, "Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with 111In, 177Lu, and 90Y for targeting bombesin receptor-expressing tumors", Cancer Res, 64(18), pp.6707~6715 (2004)
34. Zhang X, "18F labeled bombesin analogs for targeting grp receptor-expressing prostate cancer", J. Nucl. Med, 47(3), pp.492~501 (2006)

관련 논문AI추천